The Epigenetics of Drug Development and Cholesterol Levels
August 29, 2012 | James Kohl
Results from a Phase II trial of an epigenetic therapy for cardiovascular disease show promise.
By Edyta Zielinska | August 28, 2012
Excerpt: “Resverlogix’s drug targets bromodomain proteins, which detect epigenetic modifications on histone proteins and recruits additional proteins to the site. As a result, the cells produce more Apo-A1, the main component of HDL, which helps remove atherosclerotic plaques already formed.”
Isn’t the diet-responsive and presumably exercise- and pheromone-responsive hypothalamic neurogenic niche most likely to be involved in the cause and effect regulation of HDL via nutrient chemical-dependent epigenetic effects on gonadotropin releasing hormone? If so, the epigenetic “tweaking” of immense gene networks that solve problems through the exchange and the selective cancellation and modification of signals will almost no doubt be accompanied by unanticipated side effects that could be more important to health than raising HDL.